Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience

BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Karivedu, Vidhya, Eldessouki, Ihab, Taftaf, Ahmad, Zhu, Zheng, Makramalla, Abouelmagd, Karim, Nagla Abdel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501230/
https://www.ncbi.nlm.nih.gov/pubmed/31179139
http://dx.doi.org/10.1155/2019/3560640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501230/
https://www.ncbi.nlm.nih.gov/pubmed/31179139
http://dx.doi.org/10.1155/2019/3560640

Ejemplares similares